Education
About Us
Working with TipRanks
Follow Us
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
OKUR Stock Chart & Stats
$2.82
-$0.05(-0.63%)
At close: 4:00 PM EST
$2.82
-$0.05(-0.63%)
Day’s Range― - ―
52-Week Range$1.70 - $9.11
Previous CloseN/A
Volume8.61K
Average Volume (3M)86.56K
Market Cap
$37.66M
Enterprise Value$302.46M
Total Cash (Recent Filing)$70.33M
Total Debt (Recent Filing)$687.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 16, 2026EPS Estimate
-1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding12,861,672
10 Day Avg. Volume131,167
30 Day Avg. Volume86,556
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.10
Price to Sales (P/S)0.00
P/FCF Ratio-2.24
Enterprise Value/Market Cap8.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-721.85
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$25.50Price Target Upside804.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development MilestonesDosing has begun in HER2+ combination cohorts with trastuzumab and tucatinib, and initial cohort data anticipated in Q1 2026 could clarify OKI-219's competitive positioning.
PharmacokineticsSteady-state pharmacokinetic data show OKI-219 achieves exposures above levels linked to robust antitumor activity in preclinical models, supporting its biological rationale for clinical benefit.
Safety And TolerabilityOKI-219 was well tolerated across tested dose levels with no serious treatment-related adverse events reported, supporting its suitability for combination regimens.
Bears Say
Administration And Patient ConvenienceIntravenous weekly administration of OKI-219 is less patient-friendly than oral competitors, which could hinder uptake if efficacy advantages are not clear.
Competitive PressureAn intensifying competitive landscape with multiple companies advancing PI3K alpha inhibitors increases the need for OKI-219 to demonstrate clear efficacy and safety differentiation.
Efficacy SignalNo objective responses have been observed at the 900 mg dose level of OKI-219, raising concerns about single-agent activity at that dose.
OnKure Therapeutics News
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $1.70 and its highest was $9.11 in the past 12 months.
What is OnKure Therapeutics’s market cap?
OnKure Therapeutics’s market cap is $37.66M.
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is Mar 16, 2026 which is in 65 days.
How were OnKure Therapeutics’s earnings last quarter?
OnKure Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.09 earnings per share for the quarter, beating the consensus estimate of -$1.198 by $0.108.
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate is -1.14.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 12,861,672 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
OnKure Therapeutics reported an EPS of -$1.09 in its last earnings report, beating expectations of -$1.198. Following the earnings report the stock price went down -6.962%.
Which hedge fund is a major shareholder of OnKure Therapeutics?
Currently, no hedge funds are holding shares in OKUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OnKure Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.50 (804.26% Upside)
$25.50 (804.26% Upside)
Hedge Fund Trend
Decreased
By 13.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.51%
12-Months-Change
Fundamentals
Return on Equity
-115.64%
Trailing 12-Months
Asset Growth
9.34%
Trailing 12-Months
Company Description
OnKure Therapeutics
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
OKUR Stock 12 Month Forecast
Average Price Target
$25.50
▲(804.26% Upside)